homologous recombination repair deficiency
MOMA Therapeutics to Develop New PARP1 Inhibitor in Homologous Recombination-Deficient Solid Tumors
The agreement adds a new asset to the firm's pipeline of therapies targeting DNA damage response.
Researchers Aim to Confirm Benefits of Non-Hormonal Therapy for Certain Prostate Cancer Patients
Premium
Prostate cancer patients with BRCA2 and other homologous recombination repair mutations fared better on Lynparza than those without genomic alterations.
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
The firm recently started treating patients in a Phase I trial of its pol theta helicase inhibitor and filed an IND for its Werner helicase-targeted drug candidate.
Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium
The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.